Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine[1]. Dapagliflozin induces HIF1 expression and at
Molecular Weight:
408.87
Purity:
99.96
CAS Number:
[461432-26-8]
Formula:
C21H25ClO6
Target:
SGLT
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted